Studies on XXXX ) 16 E2, @entity42592 mRNA in @entity5 in relation to clinical outcome and immunological parameters.

@entity1 @entity5 @entity957 @entity73283 @entity1799 @entity1082 @entity42592 @entity405
OBJECTIVES: Three-year survival is 80% for @entity1082 ) positive tonsillar and base of @entity957 (TSCC and BOTSCC) and higher (95-100%) in @entity1 with @entity5 without HLA class I expression, or with high @entity405 (+) @entity5 -infiltrating lymphocyte (TIL) counts. The former paradoxical, the latter expected, but it is known that @entity42592 can downregulate HLA class I expression. Furthermore, upon HPV integration, E2, sometimes in combination with E5 is lost. Here, @entity1799 E2, @entity42592 mRNA was therefore examined in relation to HLA class I expression, TIL counts and survival. @entity1 AND METHODS: @entity1799 DNA positive TSCC and BOTSCC biopsies, analyzed for HLA class I and @entity405 (+) TILs, of 133 @entity1 , treated curatively between 2000 and 2011, were tested for @entity1799 E2, @entity42592 mRNA expression. Totally 127 samples could be evaluated and of these 117 @entity1 , all with @entity1799 /E7-mRNA-positive @entity5 , were included in the final analysis. RESULTS: Most @entity5 (92%) expressed E7 mRNA, and of these 64% also expressed @entity73283 mRNA. @entity1 with @entity5 lacking E2 mRNA had worse 3-year relapse and progression free survival (p<0.01 and p<0.05), while presence of E5 had no impact on clinical outcome. Furthermore, HLA class I expression and TILs were not correlated to E5 or to E2 mRNA expression. CONCLUSION: Lack of E2 but not E5 mRNA in @entity1799 positive TSCC and BOTSCC was a negative prognostic marker. Presence of @entity1799 E2, @entity42592 mRNA expression was not correlated to HLA class I expression or @entity405 (+) TILs.
